Showing 4841-4850 of 5957 results for "".
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- Retina Consultants of America Continues Growth With Partnership in Kansas and Missourihttps://modernod.com/news/retina-consultants-of-america-continues-growth-with-partnership-in-kansas-and-missouri/2478935/Retina Consultants of America (RCA) announced it has added Retina Associates, P.A. of Kansas City, based in Kansas and Missouri, to its group of practices. Retina Associates, P.A. serves the greater Kansas City, Topeka, Sedalia, and surrounding areas. Terms of the deal were no
- Eyenovia Announces FDA Acceptance of Filing of NDA for MydCombihttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/Eyenovia announced that the FDA has accepted the company’s new drug application (NDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Advance Gene Therapieshttps://modernod.com/news/saliogen-therapeutics-announces-closing-of-20-million-series-a-financing-to-advance-gene-therapies/2478925/SalioGen Therapeutics announced that it has closed a $20 million Series A financing to support the preclinical validation of the company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene the
- Study: Smartphones Could Help to Prevent Glaucoma Blindnesshttps://modernod.com/news/study-smartphones-could-help-to-prevent-glaucoma-blindness/2478918/Smartphones could be used to scan people’s eyes for early-warning signs of glaucoma, helping to prevent severe ocular diseases and blindness, a new study reveals. Soundwaves used as a mobile measurement method would detect increasing values of IOP, prompting early diagnosis and treatment.</
- Glaukos Announces Positive Phase 3 Trial Results for iLink Epi-On Investigational Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-trial-results-for-ilink-epi-on-investigational-therapy/2478917/Glaukos announced that U.S. phase 3 pivotal trial results for its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement in maximum corneal curvature (K
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- One-Dose J&J COVID-19 Vaccine Meets Criteria as Safe and Effective, FDA Report Findshttps://modernod.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/Detailed information on a Johnson & Johnson candidate vaccine for COVID-19 raises no safety concerns, according to a report released early Wednesday, according to a USA Today
- NeurOptics Launches Virtual Pupillometry Education Platformhttps://modernod.com/news/neuroptics-launches-virtual-pupillometry-education-platform/2478910/NeurOptics has launched its Pupillometry Education Symposiums platform, which includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the Neurological Pupil index (NPi) play in the assessment and screening of patients at risk of ne